Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.

Atlas Venture

EcoR1 Capital

The Column Group

The Mark Foundation for Cancer Research

AbbVie Biotech Ventures

Google Ventures

Droia Ventures

NS Investment

Accent Therapeutics, Inc. 

Excited to be sharing Accent’s pipeline progress at this year’s Triple Meeting! Maureen Lynes, Jennifer Castro, Gordon J Lockbaum, Shane Buker

https://lnkd.in/eigv_Px9

Congratulations Katalin Karikó and Drew Weissman for receiving The Nobel Prize for Medicine for your mRNA discoveries, which have led to powerful new medicines for patients! At Accent, we share this excitement for advancing the field of mRNA biology to serve patients in need.  https://lnkd.in/dUFuYQW7 

Welcome Jason Sager, Stuart Ince, and Steven Mennen!  Accent is excited to build our capabilities to bring our first two programs into the clinic! 

https://lnkd.in/evbQkmpP

An important part of early drug discovery efforts is the development of the assay toolkit that will be used to identify, validate and characterize hit compounds that can be optimized into therapeutic molecules. In Gotur et al, SLAS Discovery, 2023 (https://lnkd.in/eXPEAJGF), Accent discloses the suite of biochemical, biophysical and structural tools for DHX9 and demonstrates their utility in identifying a nucleotide analog inhibitor of the enzyme. In addition to furthering investigations into DHX9 biology, this publication also provides a framework for the development of assays for other helicases of biological interest.

Viewport Meta

IPhone / Mobile Compatible

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

Google Analytics

Google Maps

Google Universal Analytics

Typekit

Comcast

Chief Financial Officer

Nicole Heifner

President, Chief Scientific Officer and Co-Founder

Robert Copeland

Chief Executive Officer

Shakti Narayan

Vice President, Molecular Discovery

Ann Boriack-Sjodin

Chief Business Officer

David Brower

Sr. Vice President, Chemistry

Kenneth Duncan

VP Translational Medicine

Steve Blakemore

Director

Alexandra Gardino

Associate Director

Anna Ericsson

Brian Sparling

Julie Hambleton

Naveen Krishnan

Jason Rhodes

Larry Lasky

Robert A. Copeland

President, CSO & Co-Founder

Vice President of Molecular Discovery

Vice President of Chemistry

Vice President and Head of Business Development

Scott Ribich

Senior Vice President of Biology

Jamie Wilkinson

MEntal Health Therapist

East Coast Companies With Less Than $10M in Revenue (Top 10K)

Massachusetts Pharmaceutical Companies

New England Companies With Less Than $500M in Revenue (Top 10K)

Companies With Less Than $500M in Revenue (Top 10K)

Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth and differentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.

Mirae Asset Capital Life Science

Series C - Accent Therapeutics

Series B - Accent Therapeutics

Series A - Accent Therapeutics

Lexington

Massachusetts

United States

North America

Accent Therapeutics

Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting

Accent Therapeutics, Inc. on LinkedIn: #aacr24 #dhx9 #kif18a #precisiononcology #clinicaltrials

Accent Therapeutics to Present Data Supporting DHX9 and KIF18A as Compelling Therapeutic Targets at American ...

David Brower on LinkedIn: #aacr

A first-in-class inhibitor targeting DHX9, aimed at treating cancers with high unmet need, including those with BRCA loss of function and mismatch repair deficiencies.

A potential best-in-class inhibitor for KIF18A, designed to treat a broad patient population across several cancer indications, including ovarian and triple negative breast cancer.

Developing first-in-class small molecule inhibitors of ADAR1 for use as monotherapy in solid tumor indications with significant unmet need.

Inhibitors of XRN1, an RNA exonuclease, for tumors with higher IFN signaling, potentially used as monotherapy and in combination with immuno-oncology therapeutics.

Mexico

Accent Therapeutics is a biotechnology company focused on developing small molecule precision cancer therapies that target critical intracellular dependencies across various types of cancer. They leverage their expertise in RNA-modifying protein (RMP) biology to identify and exploit intracellular dependencies and develop therapeutics with far-reaching potential. Accent Therapeutics primarily serves the healthcare industry.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	631848ae
crunchbase profile	general	Nov 25, 2024 12:03 PM	ab29ee07
li profile	general	Jan 26, 2024 7:40 PM	5fd0aa87
translate crunchbase fundingrounds	general	Nov 25, 2024 1:51 PM	0cd03617
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ACCENTTX

Accent Therapeutics